Novartis’ Rhapsido cuts MS progression in Phase 3 trial, teeing up Roche battle

Novartis is planning to file for remibrutinib’s expanded approval in relapsing multiple sclerosis by next year, putting it just behind Roche’s own BTK inhibitor fenebrutinib.